San Diego-based Tentarix Biotherapeutics' US$35-million Series B financing is good news for Vancouver's Innovative Targetting Solutions , with which it shares executives and co-founders.
ITS employs 14 staff who work out of the company's 5,000-square-foot head office and lab on Virtual Way in East Vancouver. ITS is not hiring at the moment, Kang said, but he does expect the company's workload to expand. Tentarix today announced that its new US$35-million financing was led by Amplitude Ventures with participation from Gilead Sciences, Inc. , and founding investors Versant Ventures and Samsara BioCapital.
Tentarix in 2021 raised US$50 million in a financing round co-led by two San Francisco-based companies: Versant and Samsara BioCapital.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: